Tina-Quant HBA1C GEN.2
Assay, Glycosylated Hemoglobin. 510(k) K110313, from Roche Diagnostics (Indianapolis, IN). Product code LCP, class 2.
As of Nov 20, 2026, K110313 is an FDA 510(k) held by Roche Diagnostics, substantially equivalent on Dec 23, 2011 after 324 days, with no recalls tied to it in FDA's recall database.
- Review time: 324 days
- Recalls: 0
The Tina-Quant Hemoglobin A1c Gen. 2 assay is an in vitro diagnostic reagent system intended for quantitative determination of mmol/mol hemoglobin A1c (IFCC) and % hemoglobin A1c (DCCT/NGSP) in hemolysate or whole blood on Roche clinical chemistry analyzers. HbA1c determinations are useful for monitoring of long-term blood glucose control in individuals with diabetes mellitus.
- Tina-Quant Hemoglobin A1C GEN.2 Test SystemK072714 · Roche Diagnostics Corp. · Apr 18, 2008
- Q-Pad Test SystemK231465 · Qurasense · Dec 6, 2023
- Document
- 510(k) summary (PDF) ↗
- Type
- Traditional
- Received
- Feb 2, 2011
- Review panel
- Hematology
- Regulation
- 21 CFR 864.7470
One page per 510(k), De Novo and original PMA. Recalls are those FDA's recall database ties to this number; recalls of related devices that cite another number are not shown. Refreshed weekly. Predicates are read by Arca from the text of FDA's 510(k) summary PDFs, most of them scans: a device number counts when the summary names it as a predicate or as the device it is substantially equivalent to. About 97% of those read were right on a sample we checked by hand; summaries from before 2000 often name predicates without a number, so older devices show fewer. Pivotal studies are read by a model from FDA's De Novo decision summaries and PMA SSEDs; a count or result is shown only when its numbers appear in FDA's text. openFDA device 510(k), PMA and recall files